App-Quantinova.ai

Utility of Procalcitonin and Interleukin-6 As Severe Infection Biomarkers in Adulthematological and Oncological Patients. Real-Life Single Center Prospective Observational Study

Gaetano Moschetti - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sepsis

ILS-969

The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT

Juliana Silva - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Allopurinol

Haploidentical Hematopoietic Stem Cell Transplant Plus Add-Back NK Cells in Pediatric High-Risk ALL

Daniela D'Angelo - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

fludarabine tablet

Is Gaucher Disease Type 1 a Neuronopathic Disorder? Neuroradiological and Clinical Findings from Senopro_Gaucher Study

Simona Bianchi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Gaucher disease

Velaglucerase alfa

Idiopathic Multicentric Castleman Disease Interactive Disease Awareness and Educational Tool for Pathologists

Elena Sabattini - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Castleman disease

N/A

The Areal Project: How Virtual Reality Application Could Enhance Patient's Quality Time during Transfusion Therapy in Adult Patients with Thalassemia and Sickle Cell Disease

Valentino Megale - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

Challenges in Treatment Decisions and Patient-Provider Communication in Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Nirav N. Shah - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

N/A

Retrospective Observational Study of the Long-Term Safety and Efficacy Outcomes of Rituximab Biosimilar: Partial Data of RTXM83-AC-01-11 Subanalysis Study

Jessika Bridi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Rituximab biosimilar

Mantle Cell Lymphoma in Brazil: First Report from a Real-World Evidence Study of a Third World Country

Lara Gallucci Figorelle - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mantle cell lymphoma

N/A

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Claudio Cerchione - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Multiple Myeloma

Dexamethasone

Tagraxofusp Administered Concomitantly with Intrathecal Chemotherapy in Patients with BPDCN who Either Have or are Considered High-risk to Develop CNS Disease is a Safe and Effective Treatment Strategy: An Italian Multicenter Experience

Giulia Rivoli - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Blastic plasmacytoid dendritic cell neoplasm

Dexamethasone

Differences in Experiences Reported By Patients with Acute and Chronic Leukemia: A Global Survey

Zack Pemberton-Whiteley - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hematological malignancies

N/A

Risk of Unemployment Among Chronic Myeloproliferative Disorders Patients

Paolo Ditonno - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Decisional Role of Interim PET in Relapsed/Refractory Classical Hodgkin Lymphoma Treated with Begev Chemotherapy As First Salvage

Chiara Rusconi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

brentuximab vedotin

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Eric D Jacobsen - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Peripheral T-cell lymphoma

Duvelisib

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Hun Ju Lee - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hodgkin's Lymphoma

brentuximab vedotin

Clinical and Mechanistic Relationship of T-Cell Large Granular LymphocyticLeukemia (TLGL) andmonoclonal Gammopathy of Undetermined Significance(MGUS)

Danai Dima - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Waldenstrom’s macroglobulinemia

Dexamethasone

Are Growth Restricted Monochorionic Twins At Higher Risk For Neurodevelopmental Impairment Compared With Larger Co-twins?

Gloria Brembilla - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Twin–twin transfusion syndrome

N/A

Hemodynamic alterations recorded by electrical cardiometry during and after percutaneous closure of ductus arteriosus in preterm infants

Ottavio Vitelli - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Patent ductus arteriosus

N/A

Dupilumab Improves Quality of Life in Caregivers of Children With Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study

Alessandro Fiocchi - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Dupilumab

Filters

30348 Abstracts